Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Nov 11;138(19):1785-1786.
doi: 10.1182/blood.2021012759.

Improving the outlook for TP53-aberrant CLL

Michael Y Choi  1
Affiliations
Editorial

Improving the outlook for TP53-aberrant CLL

Michael Y Choi. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.Y.C. received research funding from Pharmacyclics, Abbvie, TG Therapeutics, Sunesis, Velosbio, and Oncternal Therapeutics.

Comment on

References

    1. Cramer P, Tausch E, von Tresckow J, et al. . Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations. Blood. 2021;138(19):1805-1816. - PMC - PubMed
    1. Stilgenbauer S, Schnaiter A, Paschka P, et al. . Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;138(19):3247-3254. - PubMed
    1. Rossi D, Cerri M, Deambrogi C, et al. . The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009;138(19):995-1004. - PubMed
    1. Ahn IE, Tian X, Wiestner A. Ibrutinib for chronic lymphocytic leukemia with TP53 alterations. N Engl J Med. 2020;138(19):498-500. - PMC - PubMed
    1. Stilgenbauer S, Eichhorst B, Schetelig J, et al. . Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial [corrrection published in J Clin Oncol. 2019;37(25):2299]. J Clin Oncol. 2018;138(19):1973-1980. - PubMed

MeSH terms

Substances